Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published online July 15 in the Journal of Allergy ...

These five physicians are making significant contributions at the forefront of gastroenterology. If you’d like to nominate a physician, please email [email protected]. Bincy Abraham, MD Dr ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

Introduction Benralizumab and mepolizumab are subcutaneous monoclonal antibodies licensed for the treatment of severe eosinophilic asthma. Benralizumab acts by blocking the anti-IL5 α receptor whilst ...

Benralizumab shows a positive effect in improving inspiratory capacity at rest and during exercise. Dynamic hyperinflation disappeared after treatment with benralizumab, improving daily activities and ...